CTK’s goal is to provide a Complete COVID-19 Diagnostic Solution and support market needs as the COVID-19 pandemic progresses. The COVID-19 market is ever-changing but currently can be segmented into:
Increase testing needs as cases continue to fluctuate around the world: CTK’s Aridia COVID-19 Real-Time PCR Test detects SARS-CoV-2 B.1.1.7 with the same LOD (≤ 10 RNA copies per reaction) as SARS-CoV-2 which is causing COVID-19 to spread faster.
Differentiation of other respiratory diseases: While Influenza cases were down this year, the WHO reported, “Worldwide, Influenza B detections accounted for the majority of the very low numbers of detections reported.” Simultaneous detection and differentiation of COVID-19 and Influenza A/B will become more critical as COVID-19 cases continue to fluctuate worldwide.
Identification of a COVID-19 patient clinical profile: We’re seeing an increase in demand for the following tests because they correlate to a COVID-19 patient clinical profile and aid in patient management.
|Tests Needed||Formats Offered by CTK|
|D-Dimer||D-Dimer FIA Test – F3010|
|CRP||CRP FIA Test – F0410|
|HbA1C||HbA1C FIA Test – F6100|
Vaccine Efficacy: As government agencies and manufacturers make vaccines readily available. Everyone wants to know how effective are the vaccines and can they help with acquiring herd immunity. CTK is currently developing an ELISA SARS-Cov-2 Neutralizing Antibodies Test that can detect neutralizing antibodies for plasma treatments and researchers studying vaccine efficacy.